Chennai, August 2, 2024: With a significant leadership transition, Supriya Lifescience Ltd., a pioneer in the production of Active Pharmaceutical Ingredients (APIs) worldwide, is starting a thrilling new chapter. The business is happy to announce the selection of the the next generation of the Wagh family to important leadership roles. Saloni Wagh, D., assumes the role as Managing Director, providing a new and creative perspective. Shivani Satish Wagh, a woman, takes in the capacity of Joint Managing Director, prepared to spearhead strategic expansion. Meanwhile, Dr. Satish Waman Wagh assumes the positions of Executive Chairman and Whole-Time Director, merging significant creative leadership experience. This tactical change indicates The commitment of Supriya Life Science to progress with renewed vigor and excellence.
Dr. Saloni Wagh received her Ph.D. in Chemistry from the Faculty of Science at Pacific University in Udaipur, India, and her master’s degree in science from the University of Mumbai. Dr. Saloni has over ten years of expertise in marketing and commercial operations, and she has played a crucial part in the development and success of Supriya Lifescience, especially in terms of income. Her Strategic vision and strong leadership have been essential to Supriya Lifescience’s success. reaching unprecedented heights.
Reflecting on her new role, Dr. Saloni Wagh stated, “Taking on the role of Managing Director
is both a privilege and a significant responsibility. My vision is to leverage our scientific
expertise and operational excellence to drive innovation and create value for our stakeholders.
In a rapidly evolving pharmaceutical landscape, we must remain agile and forward-thinking,
ensuring our solutions continue to meet global healthcare needs. “
Ms. Shivani Wagh brought a wealth of expertise and an exceptional educational background to Supriya Lifescience Ltd. when she joined in 2014. Shivani has a degree in management studies from Mumbai University and is an expert in marketing and international trade. two master’s degrees in international business management and commerce from the University of Manchester, UK. Her astute observations and comprehensive understanding of the The advancement of organizational success has been greatly aided by the pharmacological landscape.
“As Joint Managing Director, I am eager to advance our commitment to sustainability and innovation,” Ms. Shivani Wagh stated in response to her appointment. Through the promotion of a collaborative and continuous development culture, our objective is to improve our product offerings and broaden our presence internationally. Our priorities will be creating strategic alliances and investigating new markets to fuel our aspirations for long-term growth.
The Executive Chairman of Supriya Lifescience Ltd. is Dr. Satish Wagh, the company’s founder. His broad knowledge and inspiring leadership have played a major role in making Supriya Lifescience a well-known brand in the pharmaceutical sector. As Dr. Satish Wagh, Executive Chairman, will persist in offering strategic guidance and mentoring the group in charge.
“Looking back on our journey, I am filled with pride in the achievements of Supra Lifescience and the solid foundation we have built,” stated Dr. Satish Wagh. My priority as I move into the role of Executive Chairman will be to enable our leaders to make decisive moves in the direction of a sustainable future. I really believe that Saloni and Shivani can guide us into the next phase of expansion, upholding our dedication to quality and creativity.”
The leadership transitions take effect immediately, on August 1, 2024, and represent a major advancement in Supriya Lifescience’s path to long-term expansion and innovation. The business is still dedicated to providing top-notch pharmaceutical items and growing its global footprint in important areas.
Supriya Lifescience Ltd.’s Overview
Established in 1987, Supriya Lifescience Ltd. is a globally recognized manufacturer of active medicinal ingredients. Our state-of-the-art facility is certified by the USFDA, NMPA, EUGMP, EDQM, and Health Canada. Mumbai, India serves as the company’s headquarters, and our The facility is situated in the Ratnagiri District of Khed. Our facilities, which are worldwide compliant (EMA, US FDA, Eight operational CEPs, strong R&D, and assistance from the WHO, PMDA, TGA, KFDA, and ANVISA Fourteen USDMFs are currently in operation. Our primary business is guided by ethical ideals and EHS regulations. The company’s main goal is to provide innovators with intermediates and APIs.